Chiesi Group (Chiesi), an international research-focussed healthcare company, was present at the American Thoracic Society (ATS) meeting in San Diego (18-23 May 2018) and at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Congress in Baltimore (19-23 May 2018) with eight abstracts and an industry theatre.1-8 The data presented focussed on Trimbow (beclometasone dipropionate / formoterol fumarate / glycopyrronium), the first extrafine formulation 3-in-1 metered-dose inhaler licensed in Europe for use as a maintenance treatment for adults with moderate-to-severe COPD, who are not adequately treated by a combination of ICS/LABA.

Data presented at ATS

At ATS, five abstracts1-5 showed the results of a post-hoc analysis from the TRIBUTE[9] study, showing a new analysis of BDP/FF/G compared to IND/GLY. The other two6,7 were a post-hoc analysis from the TRINITY[10] study comparing BDP/FF/G to tiotropium, and a pooled analysis from the TRIBUTE, TRINITY and TRILOGY[11] studies on fatal events, comparing either BDP/FF/G to non-ICS containing medications or of extrafine formulation ICS-containing medications to non-ICS containing treatments.

"The new evidence of triple therapy in a single inhaler vs LABA/LAMA", commented Professor Alberto Papi, "opens new perspectives for the treatment of moderate-to-severe COPD patients". Prof. Papi, Professor and Chair of Respiratory Medicine, University of Ferrara, Italy, is the first author of the TRIBUTE study.

Professor Leonardo Fabbri, Visiting Professor University of Goteborg and co-author of the abstracts, commented: "I believe that the positive clinical effect of triple therapy and reassuring safety profile should revamp the discussion on the key role of ICS-containing triple combinations in symptomatic COPD patients with a history of exacerbations."

Data presented at ISPOR

The abstract presented at ISPOR showed the results of a cost-effectiveness analysis based on the TRIBUTE study demonstrating Chiesi’s triple therapy delivered via a single inhaler is cost-effective against IND/GLY with a cost per Quality Adjusted Life Year (QALY) gained well below the £20,000 per QALY threshold.8 The cost-effectiveness of the new triple therapy is a result of reduced exacerbations and improved Health-Related Quality of Life over IND/GLY.8

Alessandro Chiesi, Region Europe Head, Chiesi Group said, "The analysis presented today at such a prestigious congress highlights Chiesi’s commitment to providing cost-effective treatment options for a high burden and progressive disease like COPD. Chiesi has already presented Trimbow’s cost-effectiveness against LAMA alone, ICS/LABA and ICS/LABA plus LAMA (free triple) last year at the ISPOR European Congress 2017. Today we provided the missing piece of evidence of the benefit of the triple therapy over single and dual combination inhaler therapies in appropriate COPD patients. We look forward to continuing to showcase the positive benefits that our new triple therapy in a single inhaler can bring."

Register as Visitor to CPhI China 2018!